[Remote] Medical Science Liaison (MSL) Neurology – Midwest at Vor Bio

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Skills

Key technologies and capabilities for this role

NeurologyAutoimmune DiseaseTelitaciceptBAFF/APRIL inhibitorMyasthenia GravisLupusIgA nephropathySjögren’s syndromeClinical Trial ExecutionMedical StrategyScientific ExchangeHealthcare Professional EngagementClinical Researcher EngagementAdvocacy Group EngagementDisease BiologyTreatment Landscape Analysis

Questions & Answers

Common questions about this position

What is the location and travel requirement for this MSL role?

The position is based in the Midwest US, reports to the Field Medical Lead East, and requires approximately 60-80% travel.

What salary or compensation is offered for this position?

This information is not specified in the job description.

What key skills and expertise are required for the Neurology MSL role?

The role requires expertise in neurology pipeline, disease biology, and treatment landscape; strong scientific communication skills; and experience building relationships with KOLs, investigators, and stakeholders.

What is the company culture like at Vor Bio?

Vor Bio fosters a culture of belonging where every voice is heard, united by a shared mission, with emphasis on impact, growth, innovation, and collaboration across functions and geographies.

What makes a strong candidate for this MSL position?

Strong candidates will have deep scientific expertise in neurology, particularly Myasthenia Gravis, proven ability to engage KOLs and stakeholders, and experience supporting clinical trials and scientific exchange.

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters

2015Year Founded

$147.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.

Key clinical trial data updates are not expected until 2025, causing uncertainty.

Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.

The company specializes in innovative treatments for blood cancers like AML.

Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.

FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.

Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI

Try Jobo Free